Results of a Multicenter Open-Label Randomized Trial Evaluating Infusion Duration of Zoledronic Acid in Multiple Myeloma Patients (the ZMAX Trial)
James R. Berenson(Oncotherapeutics (United States)), Robert C. Collins(Palmetto Hematology Oncology), Eliza Argonza‐Aviles(Institute for Myeloma & Bone Cancer Research), Solveig G. Ericson, Simone Lake(Worcestershire Acute Hospitals NHS Trust), Timothy Lopez(Institute for Myeloma & Bone Cancer Research), Ralph V. Boccia(Center for Cancer and Blood Disorders), Ghulam Warsi(Institute for Myeloma & Bone Cancer Research)
Cited by 10
Related Papers
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Assessment of thymic output in adults after haematopoietic stemcell transplantation and prediction of T-cell reconstitution
|The Lancet|2000|579
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425